Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 9/20 | 0.57 |
| ▸ | MAX | P61244 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 9/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | IDO1 | P14902 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17546359 | 0.86 | IDO1 (0.40) | MYCMAXMEN1KMT2ANPC1 | |
| SCHEMBL12900559 | 0.83 | GSTM2 (0.51) | MYCMAXMEN1KMT2ANPC1 | |
| SCHEMBL22030234 | 0.80 | MEN1 (0.73) | MYCMAXMEN1KMT2ANPC1 | |
| SCHEMBL12040492 | 0.79 | MEN1 (0.67) | MYCMAXMEN1KMT2ANPC1 | |
| SCHEMBL13795300 | 0.78 | GSTM2 (0.61) | MYCMEN1KMT2A | |
| SCHEMBL596079 | 0.78 | GSTM2 (0.61) | MYCMEN1KMT2A | |
| SCHEMBL20101720 | 0.77 | GSTM2 (0.49) | MYCMAXMEN1KMT2AIDO1 | |
| SCHEMBL409789 | 0.76 | IDO1 (0.74) | MYCMAXMEN1KMT2ANPC1 | |
| SCHEMBL6834736 | 0.74 | IDO1 (0.76) | MYCMAXMEN1KMT2ANPC1 | |
| SCHEMBL21969702 | 0.74 | MEN1 (0.44) | MYCMAXMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025050003-A1 | HIGH-THROUGHPUT CONDENSATE MODULATOR SCREEN | TRANSITION BIO, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| US-20230149478-A1 | COMPOSITIONS AND METHODS FOR DIABETES TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2023-05-18 | — | — | US | claimed |
| EP-4125829-A2 | COMPOSITIONS AND METHODS FOR DIABETES TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021195344-A2 | COMPOSITIONS AND METHODS FOR DIABETES TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2021-09-30 | — | — | WO | claimed |
| US-12587724-B2 | Digitally enhanced microscopy for multiplexed histology | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4710112-A2 | IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS AND METHODS FOR DIAGNOSING AND TREATING CANCER - CLAUDIN 18.2 | Agilent Technologies, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4684212-A1 | IMMUNOHISTOCHEMISTRY (IHC) PTK7 SCORING PROTOCOLS AND METHODS FOR AIDING CANCER TREATMENTS | Agilent Technologies, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4659024-A1 | IMMUNOHISTOCHEMISTRY (IHC) MAGE-A4 SCORING PROTOCOLS AND METHODS FOR AIDING CANCER TREATMENTS | Agilent Technologies, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4544304-A1 | IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS AND METHODS FOR DIAGNOSING AND TREATING CANCER | Agilent Technologies, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250106488-A1 | DIGITALLY ENHANCED MICROSCOPY FOR MULTIPLEXED HISTOLOGY | VENTANA MEDICAL SYSTEMS, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2025050003-A1 | HIGH-THROUGHPUT CONDENSATE MODULATOR SCREEN | TRANSITION BIO, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250066426-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | VENTANA MED SYST INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-8865130-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2013-02-28 | — | — | US | disclosed |
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | disclosed |
| EP-2040699-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | Vanderbilt University Medical Center (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007149456-A2 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12587724-B2 | Digitally enhanced microscopy for multiplexed histology | MAP1LC3B, MAP1LC3A, MAP1LC3C | MYC 425/4885MAX 655/4885MEN1 330/4885 |
| US-20230149478-A1 | COMPOSITIONS AND METHODS FOR DIABETES TREATMENT | SLC2A1, G6PD, HK1 | MYC 847/4885MAX 2181/4885MEN1 2493/4885 |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | MYC 2577/4885MAX 3588/4885MEN1 3725/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | MYC 3836/4885MAX 4140/4885MEN1 4291/4885 |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | MYC 2577/4885MAX 3588/4885MEN1 3725/4885 |
| US-20250066426-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | PCNA, PARG, POLL | MYC 22/4885MAX 292/4885MEN1 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.